Although loss of functional β-cell mass is a hallmark of diabetes, no treatment approaches
that halt this process are currently available. We recently identified thioredoxin-interacting …

Currently, no oral medications are available for type 1 diabetes (T1D). While our recent
randomized placebo-controlled T1D trial revealed that oral verapamil had short-term beneficial …

Pancreatic beta cell loss is a key factor in the pathogenesis of type 1 diabetes (T1D), but
therapies to halt this process are lacking. We previously reported that the approved …

Diabetes is characterized by hyperglycemia, loss of functional islet beta cell mass, deficiency
of glucose-lowering insulin, and persistent alpha cell secretion of gluconeogenic glucagon. …

Beta-cell dysfunction and impaired insulin production are hallmarks of diabetes 1, but despite
the growing diabetes epidemic, the molecular mechanisms underlying this disease have …

Endoplasmic reticulum (ER) stress contributes to pancreatic beta-cell apoptosis in diabetes,
but the factors involved are still not fully elucidated. Growth differentiation factor 15 (GDF15) …

Small noncoding microRNAs have emerged as important regulators of cellular processes, but
their role in pancreatic beta cells has only started to be elucidated. Loss of pancreatic beta …

Glucagon-like peptide 1 receptor (GLP1R) agonists are widely used to treat diabetes. However,
their function is dependent on adequate GLP1R expression, which is downregulated in …

Thioredoxin-interacting protein (TXNIP) has emerged as an important factor in pancreatic
beta cell biology, and tight regulation of TXNIP levels is necessary for beta cell survival. …

Thioredoxin-interacting protein (TXNIP) is a key regulator of diabetic β-cell apoptosis and
dysfunction, and TXNIP inhibition prevents diabetes in mouse models of type 1 and type 2 …